The DOI matches its Crossref record.
Controlled Prospective Trial of Corticosteroid Therapy in Active Chronic Hepatitis
Abstract
By a method using sealed envelopes a series of patients with active chronic hepatitis who had not received corticosteroids or adrenocorticotrophic hormone was divided into two groups; one was given prednisolone and the other was used as a control. Fifty-four patients were initially included in the study over a period of 48 months, but five were subsequently withdrawn when it became clear that the diagnosis was incorrect. The corticosteroid group then contained 22 and the control group 27 patients. The two groups were reasonably well matched; the corticosteroid group, however, contained rather more females of a lower age. Although the mean serum bilirubin was higher in the control group, the mean serum aspartate aminotransferase and total globulin were higher in the corticosteroid group, indicating that that group contained more patients with a high degree of ‘activity’ of the hepatic lesion. The mean erythrocyte sedimentation rate was also higher in the corticosteroid group. An initial dose of 15 mg prednisolone daily was used in the corticosteroid group, and this was reduced whenever biochemical tests of liver function became normal or when there was evidence of severe side-effects of corticosteroids. It was subsequently stopped altogether in eight patients. During the first two to three years after inclusion to the study, the mean serum bilirubin, total globulin and albumin in the corticosteroid group showed a significant trend to normal when compared with the control group. The most significant and unexpected finding was a marked rise in serum albumin. After the investigation had been in progress for 72 months, three patients in the corticosteroid group and 15 in the control group had died at a mean of 11 (4 to 17) and 23 (1 to 63) months respectively. The difference between the mortality in the two groups is significant (P<0·01). The survivors in the two groups had been in the study for 53 (25 to 72) and 52 (29 to 72) months respectively. Four patients in the corticosteroid group had illnesses which were probably severe complications of corticosteroid therapy, and several others had minor complications. It is concluded that corticosteroid therapy should he used during the early-active phase (usually two to three years) of active chronic hepatitis and is of value in increasing life expectancy in patients with the condition. The mode of action is not clear, but it is probably related both to its immuno-suppressive properties and also an ability to stimulate albumin synthesis. The dose should be kept as low as possible, based on serum globulin and albumin concentrations, and be withdrawn when all biochemical tests of liver function return to normal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Diagnosis and management of autoimmune hepatitis
Manns, M. P., Czaja, A. J., Gorham, J. D., Krawitt, E. L., Mieli-Vergani, G., Vergani, D., & Vierling, J. M. (2010) · Hepatology · doi:10.1002/hep.23584 · Cited by 1,442
EASL Clinical Practice Guidelines: autoimmune hepatitis
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.06.030 · Cited by 1,245
Risk of Infectious Complications in Patients Taking Glucocorticosteroids
Stuck, A. E., Minder, C. E., & Frey, F. J. (1989) · Clinical Infectious Diseases · doi:10.1093/clinids/11.6.954 · Cited by 836
The presentation and diagnosis of 100 patients with primary biliary cirrhosis
Sherlock, S., & Scheuer, P. J. (1973) · New England Journal of Medicine · doi:10.1056/nejm197309272891306 · Cited by 504
Self-citationAzathioprine for Long-Term Maintenance of Remission in Autoimmune Hepatitis
Johnson, P. J., McFarlane, I. G., & Williams, R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199510123331502 · Cited by 382
Metadata
- Authors
- COOK, G. C., MULLIGAN, R., & SHERLOCK, S.
- Venue
- QJM
- Publisher
- Oxford University Press (OUP)
- Published
- 1971-04-01
- Volume
- 40
- Issue
- 2
- Pages
- 159-185
- ISSN
- 0033-5622 (ISSN-L)
- 1460-2725
- 1460-2393
- OpenAlex
- W2039049566
- Cited by
- 564
- References
- 0
- FWCI
- 34.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Controlled Prospective Trial of Corticosteroid Therapy in Active Chronic Hepatitis. https://app.cochat.ai/papers/10.1093/oxfordjournals.qjmed.a067264
- The paper
- COOK, G. C., MULLIGAN, R., & SHERLOCK, S. (1971). Controlled Prospective Trial of Corticosteroid Therapy in Active Chronic Hepatitis. QJM. https://doi.org/10.1093/oxfordjournals.qjmed.a067264
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.